Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Endocrinology ; 147(10): 4883-92, 2006 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-16809448

RESUMO

The bioactive phospholipid lysophosphatidic acid (LPA) promotes cell proliferation, survival, and migration by acting on cognate G protein-coupled receptors named LPA(1), LPA(2), and LPA(3). We profiled gene expression of LPA receptors in androgen-dependent and androgen-insensitive prostate cancer cells and found that LPA(1) gene is differentially expressed in androgen-insensitive and LPA-responsive but not androgen-dependent and LPA-resistant cells. In human prostate specimens, expression of LPA(1) gene was significantly higher in the cancer compared with the benign tissues. The androgen-dependent LNCaP cells do not express LPA(1) and do not proliferate in response to LPA stimulation, implying LPA(1) transduces cell growth signals. Accordingly, stable expression of LPA(1) in LNCaP cells rendered them responsive to LPA-induced cell proliferation and decreased their doubling time in serum. Implantation of LNCaP-LPA(1) cells resulted in increased rate of tumor growth in animals compared with those tumors that developed from the wild-type cells. Growth of LNCaP cells depends on androgen receptor activation, and we show that LPA(1) transduces Galphai-dependent signals to promote nuclear localization of androgen receptor and cell proliferation. In addition, treatment with bicalutamide inhibited LPA-induced cell cycle progression and proliferation of LNCaP-LPA(1) cells. These results suggest the possible utility of LPA(1) as a drug target to interfere with progression of prostate cancer.


Assuntos
Neoplasias da Próstata/metabolismo , Receptores de Ácidos Lisofosfatídicos/biossíntese , Northern Blotting , Ciclo Celular/fisiologia , Linhagem Celular Tumoral , Membrana Celular/efeitos dos fármacos , Membrana Celular/metabolismo , Núcleo Celular/metabolismo , Proliferação de Células , DNA de Neoplasias/biossíntese , DNA de Neoplasias/genética , Humanos , Hibridização In Situ , Masculino , Microscopia de Fluorescência , Neoplasias da Próstata/patologia , RNA Neoplásico/biossíntese , RNA Neoplásico/genética , Receptores Androgênicos/genética , Receptores de Ácidos Lisofosfatídicos/genética , Receptores de Ácidos Lisofosfatídicos/metabolismo , Transdução de Sinais/fisiologia
2.
J Biol Chem ; 280(12): 11583-9, 2005 Mar 25.
Artigo em Inglês | MEDLINE | ID: mdl-15653681

RESUMO

The androgen receptor (AR) is activated in prostate cancer patients undergoing androgen ablative therapy and mediates growth of androgen-insensitive prostate cancer cells, suggesting it is activated by nonandrogenic factors. We demonstrate that activated alpha subunit of heterotrimeric guanine nucleotide-binding G(s) protein activates the AR in prostate cancer cells and also synergizes with low concentration of androgen to more fully activate the AR. The G alpha(s) activates protein kinase A, which is required for the nuclear partition and activation of AR. These data suggest a role for G alpha(s) and PKA in the transactivation of AR in prostate cancer cells under the environment of reduced androgen levels.


Assuntos
Subunidades alfa Gs de Proteínas de Ligação ao GTP/fisiologia , Neoplasias da Próstata/metabolismo , Receptores Androgênicos/fisiologia , Transdução de Sinais/fisiologia , AMP Cíclico/fisiologia , Proteínas Quinases Dependentes de AMP Cíclico/fisiologia , Di-Hidrotestosterona/farmacologia , Humanos , Isoproterenol/farmacologia , Masculino , Neoplasias da Próstata/patologia , Receptores Adrenérgicos beta 2/fisiologia
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...